1. Shoemaker RH, McLemore TL, Abbott BJ, Fine DL, Gorelik E, Mayo JG, Fodstad O, Boyd MR. Human tumour xenograft models for use with an in vitro-based disease-oriented anti-tumour drug screening program. In: Winograd B, Peckham MJ, Pinedo, HM, eds., Human Tumour Xenografts in Anticancer Drug Development. Berlin and Heidelberg: Springer-Verlag. 1988: 115–120.
2. Staquet MJ, Byar DP, Green SB, Rozencweig M. Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy. Cancer Treat Rep 1983; 67: 753–765.
3. Venditti JM. The National Cancer Institute antitumor drug discovery program, current and future perspectives: a commentary. Cancer Treat Rep 1983; 67: 767–772.
4. Atassi G, Staquet M. The clinical predictive value of the mouse screening methods. In: Hilgard P, Hellmann K, eds. Anticancer Drug Development. Barcelona: JR Prous Publishers. 1983: 27–34.
5. Pinedo HM. Development of new anti-cancer drugs. Med Oncol Tumor Pharmacother 1986; 3: 63–69.